Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 4/20 | 0.36 |
| ▸ | SKP1 | P63208 | 4/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.36 |
| ▸ | RET | P07949 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23639174 | 0.85 | CKS1B (0.39) | KDM4EALDH1A1CKS1BSKP1SKP2 | |
| SCHEMBL23055431 | 0.85 | GRIN2B (0.38) | GRIN2B | |
| SCHEMBL23055344 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1GRIN2B | |
| SCHEMBL23639161 | 0.74 | CKS1B (0.35) | KDM4EALDH1A1CKS1BSKP1SKP2 | |
| SCHEMBL30328257 | 0.74 | CYP11B2 (0.42) | CKS1BSKP1SKP2RET | |
| SCHEMBL29974035 | 0.73 | PTPN11 (0.34) | ALDH1A1CKS1BSKP1SKP2 | |
| Hydrochloric Acid SCHEMBL23045212 | 0.73 | PTPN11 (0.34) | ALDH1A1CKS1BSKP1SKP2 | |
| SCHEMBL23055615 | 0.72 | GRIN2B (0.40) | KDM4EALDH1A1GRIN2B | |
| SCHEMBL30328474 | 0.71 | CYP11B2 (0.41) | CKS1BSKP1SKP2GRIN2BRET | |
| SCHEMBL23055613 | 0.70 | GRIN2B (0.41) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | KDM4E 3621/4885ALDH1A1 4081/4885CKS1B 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.